Fluoroquinolone resistance trends and animal drug use: a retrospective analysis  by Radostits, Otto M
International Journal of Infectious Diseases (2004) 8, 187—189
LETTER TO THE EDITOR
Fluoroquinolone resistance trends and animal
drug use: a retrospective analysis
The alleged increase in microbial risk and infec-
tious disease in communities in the past several
years apparently has been driven by the rapid and
occasionally dramatic emergence of food-borne
bacteria that are resistant to common antimicro-
bial drugs. These possible changes prompted reg-
ulatory proceedings1 regarding ﬂuoroquinolones
and their use in food-producing animals, particu-
larly chickens, due to the increase in resistance
among Campylobacter jejuni. The issue relating to
Campylobacter jejuni is that resistance to ﬂuoro-
quinolones in human Campylobacter jejuni isolates
increased from zero in 1991 to high levels (13%)
soon after the introduction of ﬂuoroquinolones in
chickens in the USA. Apparently similar data were
previously reported from Europe, where increases
in ciproﬂoxacin resistance rates (from 0% in 1982
to 11% in 1989) among human isolates of C. jejuni
were allegedly caused by ﬂuoroquinolone use in
chickens2. The purpose of this brief communica-
tion is to offer another perspective on resistance
trends related to this subject.
Clearly, the validity of these data depend on
the strength of the baseline information, which
for Campylobacter species is potentially skewed
by a laboratory practice of using nalidixic acid to
eliminate and screen campylobacter isolates. This
practice may actually have resulted in a false im-
pression of resistance. As levels of ﬂuoroquinolone
resistance exceeding 10% in C. jejuni isolates from
humans were occasionally reported in the 1970s
and 1980s, it should be understood that, before
the mid-1990s, these levels were under-estimated
by some commonly-used laboratory techniques.
Susceptibility to nalidixic acid was long used to
screen campylobacter isolates. A nalidixic acid
susceptible isolate was classiﬁed as being C. je-
juni/coli, a resistant one was classiﬁed as ‘other’.
No further testing was done on the ‘other’ campy-
lobacter isolates (including any resistant C. jejuni
isolates screened out by this procedure), since they
were then thought to be of no public health inter-
est. Thus, unknown proportions of cross-resistant
ﬂuoroquinolone-resistant C. jejuni were screened
out. Part of the increase in reported resistance
rates doubtless stems from improvements in isolate
identiﬁcation procedures, which no longer exclude
resistant C. jejuni isolates.
Consequently, the 0% baseline of 1991 may be
misrepresentative, especially in Europe, where lev-
els were somewhat higher. A review of the litera-
ture on ﬂuoroquinolone-resistant isolates of Campy-
lobacter species from humans and chickens is sum-
marized in Table 1. Against this background, the
11% resistance rate reported by Endtz in 1991 in the
Netherlands and the 13% found by the CDC in 19973
appear to be rather consistent with the general lev-
els found after the introduction of ﬂuoroquinolones
into human medicine but before their introduction
into animal medicine.
Moreover, the limitations of some studies, in-
cluding the CDC one, may be driven by the study
design and sampling methods rather than an in-
dication that signiﬁcant resistance did not exist
prior to the use of enroﬂoxacin in chickens in 1996.
Indeed, focusing on selected states, such as New
York, can even create the appearance of a strong
downward trend in resistance rates. This suggests
the necessity of increasing the CDC FoodNet sam-
ple to include many more states in order to obtain
a more valid and representative view of resistance
trends in the US.4 The 1991 Endtz study, similarly
appears to have used a sample that did not neces-
sarily represent common experience in Europe at
that time or earlier.
Two further more recent studies of human iso-
lates of Campylobacter species highlighted the
signiﬁcant problems associated with acquisition of
quinolone-resistant Campylobacter strains. Both
Rautelin et al.5 and Grieg6 observed relatively low
domestic rates of ﬂuoroquinolone resistance (10%)
but signiﬁcantly higher rates from patients who
had recently traveled to Thailand and other parts
of South East Asia as well as the Iberian penin-
sula. Indeed, the latter location has had a some-
what relaxed approach to the use of antimicrobials
for some time, including the easy availability of
non-licensed versions of ﬂuoroquinolones (with at
least 30 versions of ciproﬂoxacin readily available
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Table 1 Summary of ﬂuoroquinolone resistance of Campylobacter species isolated from humans and chickens
1981 to 1999—2000.
Year Isolated
from
Geographic
location
Number of
isolates
Species % Resistance Breakpoint Reference
1981 Human Sweden 72 C. jejuni 11% (Nali) ≥32mg/l 11
1981 Chickens Sweden 13 C. jejuni 39% (Nali) ≥32mg/l 11
1983 Humans Germany 256 C. spp 15% (Nali) ≥40g/ml 12
1990 Humans Finland 100 C. spp. 9% (Cipro) ≥8g/ml 13
1992—1995 Humans USA 97 C. spp. 12% (Cipro) NA 14
1995 Humans USA 24 C. jejuni 20% (Cipro) ≥4g/ml 15
1999 Humans Finland (D) &
Spain/Thailand (F)
678 C. jejuni &
C. coli
MIC90 0.5mg/D
64mg/l F
NA 5
1999—2000 Humans UK (D) & Overseas
(F,IP)
3489 C. jejuni D 10% Not Stated 6
F53%
IP87%
554 C. jejuni D10%
F72%
IP95%
Nali: Nalidixic acid; Cipro: Cipro-ﬂoxacin; NA: not applicable; D: domestic; F: foreign source; IP: Iberian Peninsula;
UK: United Kingdom.
in pharmacies in Spain, J Garau MD, personal com-
munication).
In addition to these confounding matters of im-
ported isolates, there are many factors which can
affect the quality of susceptibility data which need
to be improved and standardized before an effec-
tive monitoring system can be developed7. Labora-
tory identiﬁcation, standardization of testing pro-
tocols, variability between tests, selection of rele-
vant breakpoints for Campylobacter species and the
ﬂuoroquinolones, data storage and retrieval, dupli-
cate samples, clinical status, and surveillance efﬁ-
ciency are areas to consider when using these types
of data. Silley8 recently highlighted these issues
with speciﬁc regard to susceptibility testing meth-
ods and the relevance of ‘resistant MICs’ and the
lack of clinical failures in these ‘resistant’ strains.
In summary, although there is strong evidence
that resistance to ﬂuoroquinolones continues to
increase in many countries,9,10 the popular percep-
tion that resistance suddenly emerged following
the beginning of ﬂuoroquinolone use in chickens
appears to be based on an incomplete view of the
historical record in the US and Europe. Signiﬁcant
levels of ﬂuoroquinolone resistance, comparable
to many of the levels noted in the wake of en-
roﬂoxacin approval, have been documented as long
ago as the late seventies and early eighties. It is
important to consider all possible inﬂuences on
emerging bacterial resistance and not jump to one
conclusion when in fact there may bemore than one
cause.
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